+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Vectura Group plc - logo

Vectura Pharma was established in 1997, and its headquarters are in Chippenham in the U.K. Vectura Group plc researches, develops, and commercializes novel therapeutic products and drug delivery systems for the treatment of airways-related diseases Vectura entered into its first global commercialisation and development agreement with Novartis for NVA237. The company’s marketed products include Ultibro Breezhaler and Seebri Breezhaler for the treatment of chronic obstructive pulmonary disease (COPD).

Asthma Treatment Market Report and Forecast 2023-2031 - Product Thumbnail Image

Asthma Treatment Market Report and Forecast 2023-2031

  • Report
  • April 2023
  • 160 Pages
  • Global
From
Inhalation CDMO Market - Global Forecast 2025-2030 - Product Thumbnail Image

Inhalation CDMO Market - Global Forecast 2025-2030

  • Report
  • August 2025
  • 183 Pages
  • Global
From
From
Vectura Group Plc - Strategic SWOT Analysis Review - Product Thumbnail Image

Vectura Group Plc - Strategic SWOT Analysis Review

  • SWOT Analysis
  • January 2025
  • 25 Pages
From
Vectura Group Limited - Company Profile and SWOT Analysis - Product Thumbnail Image

Vectura Group Limited - Company Profile and SWOT Analysis

  • SWOT Analysis
  • January 2025
  • 41 Pages
From
Loading Indicator